Hefei Lifeon Pharmaceutical Co., Ltd. (003020.SZ) Latest Company News

Oct 29, 2026, 08:23 UTC
Lifang Pharmaceutical reported third-quarter 2026 revenue of 302 million yuan, down 13.34% year over year, and attributable net profit of 20.8095 million yuan, down 32.25%; for the first nine months, revenue was 986 million yuan, down 8.76%, and attributable net profit was 109 million yuan, down 9.86%.
Source:
- finance.sina.cn
Oct 29, 2026, 08:23 UTC
China's National Medical Products Administration approved Lifang Pharmaceutical's marketing application for dexmethylphenidate hydrochloride active pharmaceutical ingredient.
Source:
- finance.sina.cn
Oct 29, 2026, 08:22 UTC
Lifang Pharmaceutical elected Ji Tiecheng as vice chairman of its sixth board, with the term lasting until the board's term expires.
Source:
- finance.sina.cn
Oct 14, 2026, 11:24 UTC
China’s National Medical Products Administration accepted LIFU Pharmaceutical’s marketing application for miaserin hydrochloride active pharmaceutical ingredient, moving it into registration review.
Source:
- finance.sina.cn
Oct 13, 2026, 09:05 UTC
China’s National Medical Products Administration approved Lf Pharma’s chloroprocaine hydrochloride chemical API for domestic production and marketing, with the approval notice valid through October 11, 2031.
Source:
- finance.sina.cn
Sep 18, 2026, 07:51 UTC
Hefei Lifeon Pharmaceutical received acceptance from China's National Medical Products Administration for its clinical trial application for celecoxib and tramadol hydrochloride tablets (acceptance number CYHL2600101).
Source:
- finance.sina.cn
Aug 3, 2026, 03:44 UTC
Lifang Pharmaceutical announced that its doxazosin mesylate extended-release tablets and azilsartan medoxomil potassium tablets are proposed to be selected in the 12th batch of China's national centralized drug procurement, with the procurement cycle lasting until December 31, 2029.
Source:
- finance.sina.cn
Jul 9, 2026, 10:37 UTC
Lifang Pharmaceutical announced that 4 of its drug varieties were newly included in the National Essential Drug List (2026 edition).
Source:
- finance.sina.cn
- finance.sina.cn

003020.SZ

China's National Medical Products Administration approved Lifang Pharmaceutical's marketing application for dexmethylphenidate hydrochloride active pharmaceutical ingredient.

Lifang Pharmaceutical elected Ji Tiecheng as vice chairman of its sixth board, with the term lasting until the board's term expires.

China’s National Medical Products Administration accepted LIFU Pharmaceutical’s marketing application for miaserin hydrochloride active pharmaceutical ingredient, moving it into registration review.

China’s National Medical Products Administration approved Lf Pharma’s chloroprocaine hydrochloride chemical API for domestic production and marketing, with the approval notice valid through October 11, 2031.

Hefei Lifeon Pharmaceutical received acceptance from China's National Medical Products Administration for its clinical trial application for celecoxib and tramadol hydrochloride tablets (acceptance number CYHL2600101).

Lifang Pharmaceutical announced that its doxazosin mesylate extended-release tablets and azilsartan medoxomil potassium tablets are proposed to be selected in the 12th batch of China's national centralized drug procurement, with the procurement cycle lasting until December 31, 2029.

Lifang Pharmaceutical announced that 4 of its drug varieties were newly included in the National Essential Drug List (2026 edition).